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Abstract
Background: Conflicting reports on the efficacy of intra-aortic balloon pump (IABP) during percutaneous coronary
intervention (PCI) incited us to evaluate the utility of IABP in patients with acute myocardial infarction (AMI).
Methods: Randomized clinical trials comparing patients, who received IABP vs. control (no IABP) during PCI, were
hand-searched from MEDLINE, Cochrane, and EMBASE databases using the terms “intra-aortic balloon pump,
percutaneous coronary intervention, myocardial infarction, acute coronary syndrome”. Mortality rate (30-day and
6-month mortality) was the primary outcome, while the secondary outcomes included 30-day bleeding rate,
reinfarction rate, revascularization rate and stroke rate.
Results: Pooled results of the seven trials identified indicated that the 30-day and 6-month mortality rate were not
significantly different between the IABP and control groups. However, in patients with MI, but without cardiogenic
shock (CS), IABP was associated with lower odds of 30-day mortality (OR = 0.35, p = 0.015) and 6-month mortality
(OR = 0.41, p = 0.020). The pooled results of 30-day bleeding rate was not significantly higher in patients with IABP
than the control group, but for the patients with high risk PCI without CS, it was higher in patients with IABP than
the control group (OR = 1.58, p = 0.009). The re-infarction, revascularization, and the stroke rate at 30 days of
follow-up were not significantly different between the two groups.
Conclusions: The present results do not favor the clinical utility of IABP in patients suffering high-risk PCI without
CS and AMI complicated with CS. However, in patients with AMI, but without CS, IABP may reduce the 30-day and
6-month mortality rate.
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Background
Acute myocardial infarction (AMI) complicated by car-
diogenic shock (CS) is one of the leading causes of death
in patients hospitalized with AMI, and it accounts for
41.1 % of overall in-hospital mortality in a population-
based study [1, 2]. Intra-aortic balloon pump (IABP) is
the most widely used mechanical device for the treat-
ment of AMI [3, 4], since its introduction by Kantrowitz
and colleagues in early 1960s [5]. The International
Benchmark Registry (250 US and non-US centers) of
22,633 AMI patients treated with IABP suggested that
19 % of IABP implantation were for cardiogenic shock,
19.9 % for angiography and angioplasty, and 14.6 % as
an adjunct (pre-operative) to high-risk coronary artery
bypass grafting [6]. IABP support effectively reduces the
left ventricular wall stress and myocardial demand, in-
creases the coronary perfusion pressure, stroke volume,
cardiac output, and ameliorates ischemia, making it a
potentially valuable therapy in CS [3, 7, 8]. Reports else-
where suggest that IABP offers a substantial advantage
when used in combination with thrombolytic therapy
[9, 10]. In a previous study, the use of IABP in conjunc-
tion with thrombolytic therapy decreased the odds of
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death by 18 % [9]. In addition, IABP has been widely used
in the prevention of adverse catheter laboratory events
during elective high-risk PCI [11].
Despite its frequent use in the clinical practice for the
treatment of AMI, recent reports dispute whether intra-
aortic balloon counterpulsation provide any incremental
benefit to reperfusion therapy [9, 10, 12, 13]. In patients
with AMI and CS, the evidence in favor of IABP is cur-
rently limited to registry data and retrospective analyses,
and small, prospective studies without any reliable mor-
tality data [14]. A recent systematic review and meta-
analysis comparing IABP versus no IABP in patients
with AMI and CS concluded that the available data
did not provide a convincing evidence for either
benefit or harm to support the use of IABP counter-
pulsation [8]. According to the 2011 guidelines released
by the American College of Cardiology Foundation
(ACCF) and American Heart Association (AHA), IABP
counterpulsation is reasonable in non-ST-elevation myo-
cardial infarction (NSTEMI) patients for severe ischemia
that is continuing or recurs frequently despite medical
therapy, for hemodynamic instability in patients before or
after coronary angiography, and for mechanical compli-
cations of MI [15]. In 2013, ACCF/AHA has released an
updated guideline for patients with STEMI, where the
recommendation for the placement of IABP in CS was
downgraded from Class I to Class IIa, because of the lack
of clear superiority in clinical benefit and reduction of
mortality [16, 17]. Similarly, IABP was recommended in
ST-elevation myocardial infarction (STEMI) patients with
CS by the European Society of Cardiology in 2008
but an updated guideline released by European Society of
Cardiology (ESC) and the European Association for
Cardio-Thoracic Surgery (EACTS) in 2014 did not recom-
mend routinely using IABP in patients with CS [18, 19].
Use of elective IABP support in patients undergoing
high-risk PCI is still debatable. The evidence suggests
that routine IABP use does not provide clinical benefit
in patients undergoing high-risk procedures or those
with AMI in the absence of CS, but it causes a relative
reduction in the long-term all-cause mortality [11].
Bahekar and colleagues also indicated that while IABP is
not beneficial in high-risk AMI patients without cardio-
genic shock, there was significant reduction in mortality
with IABP in patients having AMI with cardiogenic
shock [20].
Considering the contrasting reports in the field and
the necessity for unified guidelines for the use of IABP, it
is of utmost importance to evaluate the clinical rele-
vance of IABP as an adjunct therapy to PCI in patients
with acute myocardial infarction with or without CS.
The present meta-analysis evaluated the clinical outcomes
of IABP as an adjunct therapy during PCI as opposed to
PCI alone. The outcomes examined include, 30-day
mortality, 6-month mortality, 30-day reinfarction rate,




The current meta-analysis was conducted in accordance
with the PRISMA guidelines [21]. We performed a
literature search of the Pubmed, Medline, Cochrane, and
EMBASE databases until December 31, 2015 using the
key words, “intra-aortic balloon pump, percutaneous
coronary intervention, myocardial infarction, acute cor-
onary syndrome, and unstable angina”. The reference
lists of relevant studies were also hand-searched.
Selection criteria
Only randomized clinical trials in adult patient popula-
tions (≧18 years), who received PCI were included in the
present meta-analysis. The intervention group received
IABP during PCI, while the control group did not.
We excluded studies that are not-randomized controlled
trials and those with no reported quantitative primary
or secondary outcomes. Non-English articles, and non-
original articles, including letters, comments, editorials,
case reports, technical reports, and personal communica-
tions were also excluded from the analysis.
Study selection and data extraction
Studies were identified by the search strategy by two
independent reviewers. Where there was uncertainty
regarding eligibility, a third reviewer was consulted.
Data extraction was also performed by two independent
reviewers, and a third reviewer was consulted to resolve
any discord. The following information was extracted
from studies that met the inclusion criteria: the name of
the first author, year of publication, study design, demo-
graphic data of subjects, patient diagnosis, prior medical
history, type of intervention, and numerical data on out-
comes of interest. The primary outcome analyzed was
mortality rate (30-day mortality, 6-month mortality) while
the secondary outcomes included 30-day bleeding rate,
30-day re-infarction rate, 30-day revascularization rate
and 30-day stroke rate.
Assessment of risk of bias
We utilized using the Cochrane Risk of Bias Tool to
assess the included studies [22]. The quality assessment
was performed by two independent reviewers and a third
reviewer was consulted for any uncertainties.
Statistical analysis
For each outcome analyzed, the odds ratio (OR) with
95 % confidence interval (CI) was calculated. Heterogen-
eity among the studies was assessed by the Cochran’s Q
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test and the I2 statistic. For Cochran’s Q, p < 0.10 indi-
cated statistically significant heterogeneity. For the I2
statistic, which indicates the percentage of the observed
between-study variability due to heterogeneity rather
than chance, heterogeneity was categorized as follows:
no heterogeneity, I2 = 0–25 %; moderate heterogeneity,
I2 = 25–50 %; large heterogeneity, I2 = 50–75 %; and ex-
treme heterogeneity, I2 = 75–100 %. All analyses were
stratified according to subgroups based on patients’ risk
factor profile (i.e., high-risk PCI without CS, MI with
CS, and MI without CS). First, pooled ORs for each out-
come within each group were calculated by the random-
effects model of analysis (DerSimonian–Laird method)
by assuming commonality in between-study variance
across subgroups. Then, a random-effect model was per-
formed to combine the estimates across subgroups. A
two-sided p value < 0.05 was considered to indicate stat-
istical significance. Sensitivity analysis was performed for
the primary outcome, short-term mortality rate, based
on the leave-one-out approach. Publication bias was
assessed by constructing a funnel plot for primary out-
come and using the Egger’s test. The absence of publica-
tion bias is indicated by the data points forming a
symmetrical, funnel-shaped distribution and p > 0.05, as
determined by the Egger’s test. All statistical analyses
were performed using the statistical software, Compre-




The flowchart for the selection of trials is outlined in
Fig. 1. Of the 113 articles identified through the litera-
ture search, 87 were excluded, and the remaining 26
articles were assessed for full text reviewing. After full
text reviewing, we excluded 17 articles for various
reasons, including having no outcome of interest, the
details of which are represented in Fig. 1. The present
meta-analysis comprises seven randomized controlled
trials reported in nine articles, which were included
for the following qualitative and quantitative analysis
[12, 13, 23–29].
Study characteristics and outcomes
A total of seven randomized controlled trials were in-
cluded in the meta-analysis. The characteristics of these
studies are summarized in Table 1. Across the studies,
the total numbers of patients ranged from 19 to 301 in
the IABP group, while it ranged from 21 to 299 in the
control (without IABP) group. Two studies (in three
Fig. 1 Flowchart of study selection. IABP, intra-aortic balloon pump; PCI: percutaneous coronary intervention
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Table 1 Summary of baseline characteristics of included studies in meta-analysis
Authors (Year) Trial name Comparison Number of
patients
Age (years) Male (%) Clinical symptom Hypertension Prior MI Prior PCI Prior CABG Prior stroke
Thiele (2012, 2013)
[12, 13]
IABP-SHOCK II IABP 301 70 (58, 78)a 67.1 MI complicated
by CS
213/296 (72.0 %) 71/300 (23.7 %) 63/299 (21.1 %) 20/300 (6.7 %) 24/300 (8.0 %)
without IABP 299 69 (58, 76)a 70.6 199/299 (66.6 %) 61/299 (20.4 %) 52/299 (17.4)% 12/299 (4.0 %) 20/299 (6.7 %)
Gu (2011) [24] – IABP 51 67.4 (9.6) 56.9 Acute STEMI or non-
STEMI without CS
35 (68.6 %) 2 (3.9 %) NR NR NR
without IABP 55 66.6 (8.0) 65.5 33 (60.0 %) 3 (5.5 %) NR NR NR
Patel (2011) [23] CRISP AMI IABP 161 56.1 (48.3, 64.3)a 82.0 Acute STEMI
without CS
39 (24.2 %) NR 3 (1.9 %) NR 0
without IABP 176 57.7 (48.6, 66.4)a 81.8 60 (34.1 %) NR 2 (1.1 %) NR 1 (0.6 %)
Perera (2010, 2013)
[26, 27]
BCIS-1 IABP 151 71 (9) 81 High risk PCI
without CS
95 (63 %) 113 (75 %) 17 (11 %) 25 (17 %) 12 (8 %)
without IABP 150 71 (10) 78 91 (61) 108 (73 %) 14 (9 %) 20 (13 %) 11 (7 %)
Prondzinsky
(2010) [28]
IABP SHOCK IABP 19 62.1 (38, 82)b 74 Acute MI
complicated
by CS
8 (42.1 %) 4 (21.1 %) NR NR NR
without IABP 21 66.1 (49, 82)b 81 10 (47.6 %) 5 (23.8 %) NR NR NR
van't Hof (1999) [29] – IABP 118 59 (10) 84 High risk PCI
without CS
NR 17 (14 %) NR 3 (3 %) NR
without IABP 120 56 (11) 84 NR 16 (13 %) NR 7 (6 %) NR
Stone (1997) [25] PAMI-II TRIAL IABP 211 64.7 (11.9) 74.9 High risk MI
without CS
116 (54.8 %) 45 (21.4 %) NR 16 (7.5 %) NR
without IABP 226 63.7 (13.0) 75.2 126 (55.7 %) 49 (21.7 %) NR 13 (5.9 %) NR
Abbreviations: IABP intra-aortic balloon pump, CS cardiogenic shock, MI myocardial infarction, STEMI ST-elevation MI, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, NR no reported













articles) were designed for patients with AMI compli-
cated by CS [12, 13, 28], while two studies included
patients with acute ST-elevation or non-ST-elevation
myocardial infarction without CS [23, 24]. The remaining
three studies (in four articles) were designed for high risk
patients with MI without CS [25–27, 29].
Outcomes of the trials are shown in Table 2. The
30-day mortality rate ranged from 1.9 to 39.7 % in the
IABP group, whereas, it ranged from 0.7 to 41.3 % in the
control group. Similarly, the IABP group had a 6-month
mortality rate of 1.9 to 48.7 %, while it was 5.2 to 49.2 %
in the no IABP group. Patients in the IABP group demon-
strated a 30-day re-infarction rate of 2 to 12.6 %, a 30-day
revascularization rate of 0.7 to 20 %, a 30-day stroke rate
of 0.7 to 2.4 %, and a 30-day bleeding rate of 3.1 to 36.0 %.
Whereas, the control, no IABP group showed a 30-day re-
infarction rate of 1.3 to 13.3 %, a 30-day revascularization
rate of 1.8 to 22 %, a 30-day stroke rate of 0 to 1.7 %, and
a 30-day bleeding rate of 1.7 to 27.4 % (Table 2).
Meta-analysis
Primary outcome: 30-day mortality rate and 6-month
mortality rate
One study [29] was excluded from the analysis, be-
cause it had not reported a 30-day mortality rate.
There was no evidence of significant heterogeneity when
data from the remaining six studies were pooled (Q = 7.4,
p = 0.192; I2 = 32.5 %). The overall analysis revealed that
the 30-day mortality rate was not significantly different in
patients with IABP, as compared to patients without IABP
(OR = 0.82, 95 % CI = 0.38 to 1.75, Z = −0.52, p = 0.605)
(Fig. 2a). In patients with MI, but without CS, the likeli-
hood of 30-day mortality was significantly lower in pa-
tients with IABP than in those without IABP (OR = 0.35,
95 % CI = 0.15 to 0.82, Z = −2.42, p = 0.015) (Fig. 2a).
Two studies [25, 28] were excluded from the final ana-
lysis as they did not report the 6-month mortality rate.
There was no evidence of significant heterogeneity when
data from the five studies were pooled (Q = 4.4, p = 0.200;
I2 = 33.2 %) (Fig. 2b). The overall analysis revealed that the
6-month mortality rate was not significantly different in
patients with IABP, as opposed to those without IABP
(OR = 0.78, 95 % CI = 0.45 to 1.33, Z = −0.93, p = 0.354).
Similarly, in patients with MI, but without CS, IABP
was associated with lower odds of 6-month mortality
(OR = 0.41, 95 % CI = 0.19 to 0.87, Z = −2.324, p = 0.020)
(Fig. 2b).
Secondary outcomes
30-day bleeding rate Two studies [28, 29] were exclu-
ded from the analysis as there was no report on the
30-day bleeding rate. There was no evidence of sig-
nificant heterogeneity when data from the five studies
were pooled (Q = 5.0, p = 0.288; I2 = 19.9 %) (Table 3).
Table 2 Summary of outcomes of included studies in meta-analysis
















IABP 301 39.7 % 48.7 % 3.0 % 20 % 0.7 % 20.7 %
without
IABP
299 41.3 % 49.2 % 1.3 % 22 % 1.7 % 20.8 %
Gu (2011) [24] IABP 51 9.8 % 17.6 % 2.0 % 3.9 % NR 11.8 %
without
IABP
55 27.3 % 32.7 % 3.6 % 1.8 % NR 3.6 %
Patel (2011) [23] IABP 161 1.9 % 1.9 % NR NR 1.9 % 3.1 %
without
IABP
176 4.0 % 5.2 % NR NR 0.6 % 1.7 %
Perera (2010, 2013)
[26, 27]
IABP 151 2.0 % 4.6 % 12.6 % 0.7 % 1.3 % 19.2 %
without
IABP
150 0.7 % 7.4 % 13.3 % 2.7 % 0 11.3 %
Prondzinsky (2010)
[28]
IABP 19 36.8 % NR NR NR NR NR
without
IABP
21 28.6 % NR NR NR NR NR
van't Hof (1999)
[29]
IABP 118 NR 10 % NR NR NR NR
without
IABP
120 NR 8 % NR NR NR NR
Stone (1997) [25] IABP 211 4.3 % NR 6.2 % 4.7 % 2.4 % 36.0 %
without
IABP
226 3.1 % NR 8.0 % 4.0 % 0 27.4 %
Abbreviations: IABP intra-aortic balloon pump, NR no reported
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The overall analysis revealed that the 30-day bleeding rate
was significantly higher in patients with IABP compared
to those without IABP (OR = 1.39, 95 % CI = 0.86 to 2.24,
Z = 1.36, p = 0.174). The results of subgroup analysis
showed that patients with IABP had higher odds of 30-day
bleeding than those without IABP in the subgroup of
high-risk PCI without CS (OR = 1.59, 95 % CI = 1.12 to
2.24, Z = 2.63, p = 0.009) (Table 3).
30-day reinfarction rate Three studies [23, 28, 29] were
excluded from the analysis, since a 30-day re-infarction
rate was not reported. There was no evidence of signifi-
cant heterogeneity when data from the remaining four
studies were pooled (Q = 2.64, p = 0.450; I2 = 0 %). The
overall analysis revealed that the 30-day reinfarction rate
was not significantly different in patients with IABP as
compared to patients without IABP (OR = 0.96, 95 % CI =
0.61 to 1.51, Z = −0.16, p = 0.875). No significant results
were observed in the subgroup analysis according to the
patients’ risk factor profile (Table 3).
30-day revascularization rate Three studies [23, 28, 29]
were excluded from the analysis as the 30-day revascu-
larization rate was not reported. There was no evidence
of significant heterogeneity when data from the four
studies were pooled (Q = 2.23, p = 0.526; I2 = 0 %). The
overall analysis revealed that the 30-day revascularization
rate was not significantly different between the two groups
(IABP vs. control, no IABP) (OR = 0.90, 95 % CI = 0.54 to
1.51, Z = −0.40, p = 0.688). No significant results were
found in the subgroup analysis based on patients’ risk fac-
tor profile (Table 3).
30-day stroke rate Three studies [24, 28, 29] were ex-
cluded from the final analysis as no data on 30-day stroke
rate was reported. There was no evidence of significant
heterogeneity when data from the remaining four studies
were pooled (Q = 5.59, p = 0.133; I2 = 46.3 %). The overall
analysis revealed that the 30-day stroke rate was not
significantly different in patients with IABP as compared
to those without IABP (OR = 1.58, 95 % CI = 0.51 to 4.86,
Fig. 2 Forest plots showing the results for the meta-analysis of (a) 30-day mortality rate, (b) 6-month mortality rate. Abbreviations: IABP, intra-aortic
balloon pump; CI, confidence interval
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Z = 0.79, p = 0.428). No significant results were found in
the subgroup analysis according to the patient risk factor
profile (Table 3).
Sensitivity analysis
The results of the meta-analysis using the leave-one-out
approach to assess sensitivity is summarized in Fig. 3a
(30-day mortality) and Fig. 3b (6-month mortality). For
30-day bleeding rate, 30-day reinfarction rate, 30-day re-
vascularization rate, and 30-day stroke rate, results were
not shown. The direction and magnitude of the pooled
estimates for 30-day mortality and 6-month mortality
did not vary considerably, indicating that the meta-
analysis had good reliability.
Publication bias
There was no evidence of significant publication bias for the
30-day mortality rate as assessed by the Egger’s test (Fig. 4).
The results reveal no publication bias for the 30-day mortal-
ity rate (p= 0.472). Publication bias was not assessed for the
other five outcomes, because more than five studies are re-
quired to detect funnel plot asymmetry [30].
Assessment of risk of bias
The results of the assessments of risk of bias are pre-
sented in Fig. 5. The risk of potential bias of individual
Table 3 Results of meta-analysis for secondary outcomes
Outcomes No. of studies OR (95 % CI) P
30-day bleeding
High-risk PCI without CS 2 1.585 (1.124, 2.235) 0.009*
MI with CS 1 0.992 (0.668, 1.472) 0.967
MI without CS 2 2.451 (0.826, 7.273) 0.106
Total 5 1.391 (0.864, 2.238) 0.174
30-day reinfarction rate
High-risk PCI without CS 2 0.851 (0.517, 1.400) 0.525
MI with CS 1 2.273 (0.692, 7.464) 0.176
MI without CS 1 0.530 (0.047, 6.028) 0.609
Total 4 0.964 (0.614, 1.514) 0.875
30-day revascularization rate
High-risk PCI without CS 2 0.749 (0.180, 3.118) 0.691
MI with CS 1 0.883 (0.501, 1.554) 0.665
MI without CS 1 2.204 (0.194, 25.071) 0.524
Total 4 0.900 (0.538, 1.505) 0.688
30-day stroke rate
High-risk PCI without CS 2 7.959 (0.974, 65.021) 0.053
MI with CS 1 0.393 (0.076, 2.043) 0.267
MI without CS 1 3.323 (0.342, 32.271) 0.301
Total 4 1.576 (0.511, 4.861)
Abbreviations: CS cardiogenic shock, MI myocardial infarction
* P < 0.05
Fig. 3 Results of sensitivity analysis to examine the influence of individual studies on pooled estimates as determined using the leave-one-out
approach: (a) 30-day mortality rate, (b) 6-month mortality rate. Abbreviations: IABP, intra-aortic balloon pump; CI, confidence interval
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studies is given in Fig. 5a, while the risk of bias of all
included studies is represented in Fig. 5b. The bias in
the results can be mainly attributed to the performance
bias, because none of the included studies could blind
the patients or the study personnel in-charge.
Discussion
IABP increase diastolic aortic pressure, which improves the
diastolic coronary flow. IABP simultaneously reduces sys-
tolic aortic pressure, which in turn decrease the afterload
and oxygen consumption of the myocardium [3, 8, 29]. In
addition to AMI, IABP has been widely used in indi-
cations including, CS, high risk percutaneous coronary
intervention and cardiac surgery for hemodynamic sup-
port [3, 14]. Besides its long-standing clinical use as the
main form of mechanical circulatory support, the long-
term benefits of IABP are still controversial due to the
paucity of prospective, randomized clinical trials [14]. The
current study was undertaken to broaden our understand-
ing through a systematic review and meta-analysis of the
existing literature in the clinical practice of IABP in terms
of AMI with/without CS as well as in patients with high
risk PCI. The pooled results of the current meta-analysis
do not favor the overall survival and hence, the clinical
utility of IABP, in patients suffering high-risk PCI without
CS and AMI complicated with CS. However, for patients
with MI but without CS, IABP may reduce 30-day
and 6-month mortality rate.
CS is a clinical state of hypoperfusion characterized by
a systolic pressure, 90 mmHg and a central filling pressure
(wedge pressure), .20 mmHg, or a cardiac index,1.8 L/
min/m2, and caused by the extensive loss of viable myo-
cardial tissue. IABP is recommended by ACCF/AHA
guideline (2013), which stated that “The use of IABP
counterpulsation can be useful for patients with cardio-
genic shock after STEMI who do not quickly stabilize with
pharmacological therapy. (Class IIa recommendation,
Level of evidence: A)” [16]. However, Sjauw et al. (2009)
have challenged the existing general recommendations for
the use of IABP in patients with ST-segment elevation
myocardial infarction (STEMI) complicated by CS and
have confirmed that IABP do not offer any advantage
during PCI [10]. These findings were further supported by
a well-powered, prospective, randomized clinical trial
(IABP-SHOCK II trial) [12, 13], where they demonstrated
that IABP did not reduce 30-day mortality or 12 month
all-cause mortality in patients undergoing early revascu-
larization for myocardial infarction complicated by cardio-
genic shock. In addition, in patients with acute anterior
STEMI without shock, no reduction in the infarct size
was noted for IABP along with PCI as compared to
PCI alone [23]. The current results are in agreement
with the previous meta-analyses, [8, 10] where the
benefit of adjunctive IABP therapy was not statistically
significant in STEMI patients complicated by CS, and
IABP did not show a significant reduction of mortality in
Fig. 4 Funnel plot for publication bias for 30-day mortality. White circles represent observed studies. White rhombuses represent observed
combined effect size
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Fig. 5 Summary of quality assessment. a Risk of potential bias of individual study, b Risk of bias of all included studies
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patients with AMI and cardiogenic shock. In an updated
ESC/EACTS Guidelines in 2014, routine use of IABP in
patients with cardiogenic shock was not recommended
(Class III recommendation, Level of evidence: A) [19].
IABP insertion should only be considered in patients with
haemodynamic instability/cardiogenic shock due to mech-
anical complications (Class IIa recommendation, Level of
evidence: C) [19].
The role of IABP support in the management of high-
risk patients with AMI remains unclear. In a EURO-
TRANSFER registry of unselected patients with STEMI
complicated by CS, the long term outcomes were similar
between the high risk population with IABP and the low
risk non-IABP patients, indicating that IABP may be ef-
fective in high risk patients [31]. Our result is consistent
with the previous systematic review and meta-analysis
that, in high-risk STEMI patients without CS, the major-
ity of the studies could not demonstrate an efficacy
benefit for IABP as compared to the control group in
terms of in-hospital mortality, left ventricular ejection
fraction, and rate of recurrent ischemia [20, 32].
However, in patients with MI without CS, our meta-
analysis showed a different result from the previous re-
ports. A recent meta-analysis reported by Ahmad et al.
found that IABP treatment had no statistically significant
effect on mortality. This outcome was consistent when
the articles were stratified by the presence or absence of
CS [33]. A meta-analysis of six randomized trials con-
cluded that IABP did not reduce all-cause death [34]. In
a systematic review including randomized controlled
trials published between 1981 and 2011, the majority of
the studies could not demonstrate a beneficial effect of
IABP therapy in patients with STEMI without CS [32].
Moreover, a retrospective analysis on the role of IABP in
patients with acute MI without CS also found no differ-
ence in the in-hospital rate of cardiac death among pa-
tients who received IABP at the time of their coronary
revascularization and the control group [35]. However, we
found that IABP may reduce 30-day and 6-month mortal-
ity rate in patients with MI, but without CS. This is in
agreement with a systematic review reported by Ye et al.
where they reported that while IABP did not reduce mor-
tality within 2 months and 6–12 months of intervention
in AMI patients with CS, but it can reduce 6–12 month
mortality in patients with AMI without CS [36]. Since we
only included two RCTs in this subgroup, the clinical
benefit of IABP in patients with acute MI without CS re-
mains to be explored further in future studies.
Though IABP did not offer any major advantage dur-
ing primary PCI, it was effective as an adjunctive therapy
to thrombolysis in patients with MI. Subgroup analysis
even showed that, in patients with high-risk PCI without
CS, IABP had higher odds of 30-day bleeding than those
without IABP. Correspondingly, we did not observe any
difference in the secondary outcomes like, 30-day mor-
tality rate, 6-month mortality, 30-day reinfarction rate,
30-day revascularization rate, or 30-day stroke rate
between the IABP and the control groups. The meta-
analysis reported by Cassese et al. had similar conclusion
that IABP significantly reduced recurrent myocardial is-
chemia and increased the risk of bleeding [34]. The meta-
analysis reported by Bahekar et al. also found that IABP
significantly increased the risk of moderate to major
bleeding [20]. Major bleeding associated with IABP, thus
requiring increased transfusion, was also demonstrated in
retrospective studies [35]. For revascularization rate after
treatment, the meta-analysis reported by Sjauw et al.
found that IABP showed a significantly higher revasculari-
zation rate compared to patients without support [10].
Though the majority of the recent reviews had failed to
demonstrate a survival benefit for IABP, it was shown to
have some beneficial effect on hemodynamic parameters,
like cardiac index, mean arterial pressure, and pulmonary
capillary wedge pressure [8]. It has been suggested that
the use of IABP should be reserved for patients with se-
vere hemodynamic compromise [29]. However, it should
be noted that the improved hemodynamic status does not
always translate into improved survival outcomes. In a re-
cent commentary, Grieshaber and colleagues have sug-
gested that IABP might have a greater effect in patients
with reduced coronary perfusion and those with severely
reduced left ventricular function, like in patients with
AMI who need to be temporized prior to cardiac bypass
surgery [7]. We did not analyze the hemodynamic param-
eters due to the limited number of data available in our in-
cluded studies.
The current meta-analysis is an updated review of the
available data on the utility of IABP during PCI. How-
ever, there are several limitations to our analysis, includ-
ing the limited number of included studies in each
subgroup and the heterogeneity in patient characteristics
among the studies. The publication bias is difficult to in-
terpret due to the limited number of included studies.
Furthermore, there is a potential bias resulting from the
inadequate blinding of patients and the study personnel.
Conclusions
The included RCTs demonstrate that IABP may reduce
30-day and 6-month mortality rate in patients with MI
but without CS. In addition, for the patients with high
risk PCI without CS, receiving IABP may have higher
30-day bleeding rate in compared to those without
IABP. No clinical benefit of IABP was demonstrated in
patients suffering high-risk PCI without CS and AMI
complicated with CS. Future studies comprising of large,
multicentric, prospective randomized trials should be
undertaken to validate the current data and also to con-
firm or disprove its efficacy in patients with different
Zheng et al. BMC Cardiovascular Disorders  (2016) 16:148 Page 10 of 12
diagnosis, including patients with high to moderate risk
of CS and patients with AMI with and without CS.
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